Намаляването на продължителността на лечение при пациенти, инфектирани с генотип 2 или 3 с ВВН (> 800 000 IU/ ml) на изходно
Shortening the treatment duration in patients infected with genotype 2 or 3 with HVL (> 800,000 IU/ mL) at baseline who become HCV negative by week 4 should be considered with more caution as this may significantly negatively impact the sustained virological response (see Table 1).